Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli Lilly’s weight-loss drug. This comes after ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.